Information regarding Ingrezza's precise market share for 2024 or 2025 is not publicly available in the provided text. Market share data is typically proprietary and released by the companies themselves or by market research firms.
When does Ingrezza's patent exclusivity expire?
Ingrezza (valbenazine) has patent protection that is expected to extend through 2027 for its primary indications [1]. However, the exact expiry dates for all patents related to Ingrezza can be complex, involving multiple patents covering different aspects of the drug, such as its formulation, method of use, and manufacturing processes [2].
Who makes Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences [3].
What is Ingrezza used to treat?
Ingrezza is approved to treat tardive dyskinesia (TD) and chorea associated with Huntington's disease [3]. Tardive dyskinesia is a movement disorder that can cause repetitive, involuntary movements, often as a side effect of long-term use of dopamine-blocking medications [4]. Huntington's disease is a genetic disorder that affects muscle coordination and leads to involuntary, jerky movements [5].
How does Ingrezza work?
Ingrezza is a selective VMAT2 inhibitor [3]. VMAT2 is a protein that plays a role in the transport of neurotransmitters like dopamine. By inhibiting VMAT2, Ingrezza is thought to reduce the amount of dopamine available in certain parts of the brain, which helps to control the involuntary movements associated with tardive dyskinesia and chorea [3].
What are the side effects of Ingrezza?
Common side effects reported for Ingrezza include somnolence (drowsiness) and fatigue [3]. It is important for patients to discuss potential side effects with their healthcare provider.
What are the treatment options for tardive dyskinesia?
Besides Ingrezza, other medications approved for the treatment of tardive dyskinesia include Austedo (deutetrabenazine) [6]. Both Ingrezza and Austedo are VMAT2 inhibitors but differ in their specific mechanisms and pharmacokinetic profiles [7].
What is the pricing and insurance coverage for Ingrezza?
Pricing and insurance coverage for Ingrezza can vary significantly based on individual insurance plans, patient assistance programs, and geographic location. Patients are often encouraged to contact their insurance provider and the manufacturer for specific details regarding cost and coverage [8].
What is the clinical data supporting Ingrezza's use?
Clinical trials have demonstrated Ingrezza's efficacy in reducing the severity of involuntary movements in patients with tardive dyskinesia [3]. For instance, studies like the Penelitian Kualitatif dalam Jaringan dan Eksplorasi Studi Tardive Dyskinesia (KINETIC) trial showed significant improvements in the Abnormal Involuntary Movement Scale (AIMS) scores for patients treated with Ingrezza [9].
Can Ingrezza be used off-label?
While Ingrezza is approved for specific indications, physicians may prescribe medications for conditions other than those officially approved by regulatory agencies. However, information on the extent of off-label use for Ingrezza is not detailed in the provided text.
What is the regulatory status of Ingrezza?
Ingrezza has received approval from the U.S. Food and Drug Administration (FDA) for its indicated uses [3].
Sources:
[1] DrugPatentWatch.com
[2] DrugPatentWatch.com
[3] Neurocrine Biosciences
[4] National Institute of Neurological Disorders and Stroke
[5] National Institute of Neurological Disorders and Stroke
[6] FDA
[7] DrugPatentWatch.com
[8] Ingrezza.com
[9] DrugPatentWatch.com